Compare Tripadvisor Inc Common Stock (TRIP) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tripadvisor Inc Common Stock vs Zoetis Inc — how do they compare? Tripadvisor Inc Common Stock trades at $8.76 (market cap $1.01B), while Zoetis Inc trades at $74.52 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 29.9× Tripadvisor Inc Common Stock's market cap, and Zoetis Inc pays a 2.9% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tripadvisor Inc Common Stock for 57 Days and Zoetis Inc for 70 Days on average.
| TRIP | ZTS | |
|---|---|---|
Market Cap | $1.01B | $30.20B |
Volume | 3,004,748 | 6,175,327 |
Sector | Consumer Cyclical | Health |
52-Week High | $16.72 | $147.53 |
52-Week Low | $8.04 | $69.09 |
Typical Hold Time | 57 Days | 70 Days |
Enterprise Value | $1.06B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TripAdvisor (TRIP) trades at $8.63, down 42% over the past year and near its 52-week low of $8.27. The stock shows bearish technical signals with recent earnings misses and declining revenue projections for 2026. Despite a low P/S ratio of 0.57, the company faces challenges from AI-driven competition eroding its core travel platform relevance.
The investment outlook remains cautious with analysts divided (21% Buy, 63% Hold) and a $13.58 price target suggesting 57% upside. Key risks include persistent search pressure, TheFork subsidiary sale execution, and competitive threats from AI travel tools. Positive cash flow from operations provides some stability amid the challenging transition.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.
Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
